Interleukin	B-GP
-	I-GP
17	I-GP
-	O
positive	O
mast	O
cells	O
influence	O
outcomes	O
from	O
BCG	B-OG
for	O
patients	O
with	O
CIS	B-DS
:	O
Data	O
from	O
a	O
comprehensive	O
characterisation	O
of	O
the	O
immune	O
microenvironment	O
of	O
urothelial	B-DS
bladder	I-DS
cancer	I-DS

Competing	O
Interests	O
:	O
RT	O
Bryan	O
has	O
contributed	O
to	O
advisory	O
boards	O
for	O
Olympus	O
Medical	O
Systems	O
with	O
regard	O
to	O
narrow	O
band	O
imaging	O
cystoscopy	O
.	O

ND	O
James	O
has	O
contributed	O
to	O
advisory	O
boards	O
for	O
Merck	O
USA	O
and	O
Pierre	O
Fabre	O
.	O

This	O
does	O
not	O
alter	O
our	O
adherence	O
to	O
PLOS	O
ONE	O
policies	O
on	O
sharing	O
data	O
and	O
materials	O
.	O

This	O
does	O
not	O
alter	O
our	O
adherence	O
to	O
PLOS	O
ONE	O
policies	O
on	O
sharing	O
data	O
and	O
materials	O
.	O

The	O
tumour	B-DS
immune	O
microenvironment	O
is	O
considered	O
to	O
influence	O
cancer	B-DS
behaviour	O
and	O
outcome	O
.	O

Using	O
a	O
panel	O
of	O
markers	O
for	O
innate	O
and	O
adaptive	O
immune	O
cells	O
we	O
set	O
out	O
to	O
characterise	O
and	O
understand	O
the	O
bladder	B-DS
tumour	I-DS
microenvironment	O
of	O
114	O
patients	O
from	O
a	O
prospective	O
multicentre	O
cohort	O
of	O
newly	O
-	O
diagnosed	O
bladder	B-DS
cancer	I-DS
patients	O
,	O
followed	O
-	O
up	O
for	O
4	O
.	O
33	O
±	O
1	O
.	O
71	O
years	O
.	O

We	O
found	O
IL	B-GP
-	I-GP
17	I-GP
-	O
positive	O
cells	O
were	O
significantly	O
increased	O
in	O
primary	O
and	O
concomitant	O
carcinoma	B-DS
in	I-DS
situ	I-DS
(	O
CIS	B-DS
),	O
p	O
<	O
0	O
.	O
0001	O
,	O
a	O
highly	O
malignant	O
lesion	O
which	O
is	O
the	O
most	O
significant	O
single	O
risk	O
factor	O
for	O
disease	O
progression	O
.	O

Further	O
characterisation	O
of	O
the	O
tumour	B-DS
immunophenotype	O
identified	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
as	O
predominantly	O
mast	O
cells	O
rather	O
than	O
T	O
-	O
cells	O
,	O
in	O
contrast	O
to	O
most	O
other	O
tumour	B-DS
types	O
.	O

Expression	O
of	O
the	O
IL	B-GP
-	I-GP
17	I-GP
-	I-GP
receptor	I-GP
in	O
bladder	B-DS
tumours	I-DS
,	O
and	O
functional	O
effects	O
and	O
gene	O
expression	O
changes	O
induced	O
by	O
IL	B-GP
-	I-GP
17	I-GP
in	O
bladder	B-DS
tumour	I-DS
cells	O
in	O
vitro	O
suggest	O
a	O
role	O
in	O
tumour	B-DS
behaviour	O
.	O

Finally	O
,	O
we	O
assessed	O
the	O
effects	O
of	O
IL	B-GP
-	I-GP
17	I-GP
in	O
the	O
context	O
of	O
patient	O
outcome	O
,	O
following	O
intravesical	O
BCG	B-OG
immunotherapy	O
which	O
is	O
the	O
standard	O
of	O
care	O
;	O
higher	O
numbers	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
were	O
associated	O
with	O
improved	O
event	O
-	O
free	O
survival	O
(	O
p	O
=	O
0	O
.	O
0449	O
,	O
HR	O
0	O
.	O
2918	O
,	O
95	O
%	O
CI	O
0	O
.	O
08762	O
–	O
0	O
.	O
9721	O
)	O
in	O
patients	O
with	O
primary	O
and	O
concomitant	O
CIS	B-DS
(	O
n	O
=	O
41	O
),	O
we	O
propose	O
a	O
model	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
Mast	O
cells	O
mechanism	O
of	O
action	O
.	O

Thus	O
,	O
in	O
the	O
context	O
of	O
bladder	B-DS
CIS	I-DS
,	O
IL	B-GP
-	I-GP
17	I-GP
+	O
mast	O
cells	O
predict	O
favourable	O
outcome	O
following	O
BCG	B-OG
immunotherapy	O
indicative	O
of	O
a	O
novel	O
mechanism	O
of	O
BCG	B-OG
immunotherapy	O
in	O
UBC	B-DS
and	O
could	O
form	O
the	O
basis	O
of	O
a	O
stratified	O
approach	O
to	O
treatment	O
.	O

Introduction	O

Bladder	B-DS
cancer	I-DS
is	O
the	O
seventh	O
most	O
common	O
cancer	B-DS
in	O
Western	O
society	O
,	O
with	O
a	O
global	O
incidence	O
of	O
over	O
380	O
,	O
000	O
[	O
1	O
,	O
2	O
].	O

In	O
Western	O
populations	O
90	O
%	O
of	O
bladder	B-DS
cancers	I-DS
are	O
transitional	B-DS
cell	I-DS
carcinoma	I-DS
of	O
urothelial	O
origin	O
(	O
urothelial	B-DS
bladder	I-DS
cancer	I-DS
,	O
UBC	B-DS
)	O
and	O
most	O
patients	O
(	O
75	O
–	O
85	O
%)	O
present	O
with	O
non	B-DS
-	I-DS
muscle	I-DS
invasive	I-DS
bladder	I-DS
cancer	I-DS
(	O
NMIBC	B-DS
:	O
stages	O
Ta	O
/	O
T1	O
/	O
Tis	O
)	O
[	O
3	O
].	O

Patients	O
with	O
NMIBC	B-DS
are	O
initially	O
treated	O
by	O
transurethral	O
tumour	B-DS
resection	O
(	O
TURBT	O
),	O
but	O
recurrence	O
is	O
commonplace	O
occurring	O
in	O
up	O
to	O
80	O
%	O
of	O
patients	O
[	O
4	O
].	O

Progression	O
to	O
muscle	B-DS
-	I-DS
invasive	I-DS
bladder	I-DS
cancer	I-DS
(	O
MIBC	B-DS
:	O
stages	O
T2	O
+)	O
occurs	O
in	O
up	O
to	O
45	O
%	O
of	O
patients	O
[	O
4	O
,	O
5	O
],	O
and	O
represents	O
a	O
critical	O
step	O
in	O
the	O
disease	O
course	O
,	O
carrying	O
a	O
5	O
-	O
year	O
survival	O
rate	O
of	O
only	O
27	O
–	O
50	O
%,	O
necessitating	O
more	O
radical	O
therapies	O
(	O
including	O
surgery	O
,	O
chemotherapy	O
or	O
radiotherapy	O
)	O
[	O
6	O
,	O
7	O
].	O

The	O
most	O
significant	O
single	O
risk	O
factor	O
for	O
progression	O
to	O
MIBC	B-DS
is	O
the	O
presence	O
of	O
primary	O
or	O
concomitant	O
carcinoma	B-DS
in	I-DS
situ	I-DS
(	O
CIS	B-DS
)	O
[	O
8	O
].	O

This	O
flat	O
high	O
-	O
grade	O
dysplasia	O
is	O
highly	O
malignant	O
with	O
significant	O
potential	O
for	O
invasion	O
;	O
patients	O
diagnosed	O
with	O
CIS	B-DS
therefore	O
undergo	O
additional	O
treatments	O
following	O
TURBT	O
,	O
principally	O
repeated	O
cycles	O
of	O
intravesical	O
Bacillus	B-OG
Calmette	I-OG
-	I-OG
Guerin	I-OG
(	O
BCG	B-OG
)	O
immunotherapy	O
in	O
a	O
regimen	O
of	O
induction	O
and	O
maintenance	O
[	O
9	O
].	O

Despite	O
these	O
efforts	O
,	O
50	O
%	O
of	O
patients	O
relapse	O
and	O
are	O
then	O
at	O
high	O
risk	O
of	O
progression	O
to	O
MIBC	B-DS
,	O
with	O
poor	O
prognosis	O
[	O
10	O
].	O

There	O
are	O
currently	O
no	O
prognostic	O
markers	O
to	O
identify	O
those	O
CIS	B-DS
patients	O
who	O
will	O
respond	O
to	O
therapy	O
and	O
those	O
who	O
will	O
relapse	O
[	O
9	O
].	O

The	O
tumour	B-DS
microenvironment	O
is	O
important	O
in	O
the	O
initiation	O
,	O
growth	O
and	O
progression	O
of	O
cancer	B-DS
,	O
and	O
multiple	O
interactions	O
between	O
tumour	B-DS
,	O
stromal	O
and	O
immune	O
cells	O
have	O
been	O
described	O
[	O
11	O
].	O

The	O
contribution	O
made	O
by	O
immune	O
cells	O
is	O
complex	O
—	O
many	O
different	O
cell	O
types	O
have	O
been	O
identified	O
within	O
tumours	B-DS
,	O
and	O
the	O
effects	O
of	O
a	O
particular	O
infiltrate	O
can	O
vary	O
between	O
different	O
tumours	B-DS
[	O
6	O
,	O
7	O
].	O

With	O
regard	O
to	O
NMIBC	B-DS
,	O
the	O
potential	O
role	O
of	O
the	O
immune	O
system	O
is	O
of	O
particular	O
interest	O
since	O
the	O
most	O
successful	O
treatment	O
currently	O
utilised	O
,	O
BCG	B-OG
immunotherapy	O
,	O
is	O
thought	O
to	O
act	O
by	O
inducing	O
an	O
acute	O
inflammatory	O
response	O
in	O
the	O
bladder	O
wall	O
[	O
12	O
,	O
13	O
].	O

Studies	O
thus	O
far	O
have	O
examined	O
macrophages	O
[	O
14	O
],	O
T	O
cells	O
[	O
15	O
,	O
16	O
]	O
and	O
the	O
inflammatory	O
response	O
provoked	O
by	O
BCG	B-OG
[	O
17	O
],	O
but	O
many	O
questions	O
remain	O
unanswered	O
[	O
12	O
].	O

Therefore	O
,	O
our	O
objective	O
was	O
to	O
comprehensively	O
characterise	O
the	O
immune	O
microenvironment	O
of	O
UBC	B-DS
,	O
and	O
its	O
influence	O
on	O
outcomes	O
,	O
utilising	O
tumour	B-DS
material	O
prospectively	O
collected	O
from	O
newly	O
-	O
diagnosed	O
patients	O
[	O
18	O
].	O

Material	O
and	O
methods	O

Patient	O
samples	O

Formalin	O
fixed	O
paraffin	O
embedded	O
(	O
FFPE	O
)	O
tissue	O
and	O
snap	O
-	O
frozen	O
tissue	O
samples	O
of	O
newly	O
-	O
diagnosed	O
primary	O
UBCs	B-DS
were	O
obtained	O
from	O
the	O
Bladder	B-DS
Cancer	I-DS
Prognosis	O
Programme	O
(	O
BCPP	O
—	O
clinicaltrials	O
.	O
gov	O
identifier	O
NCT00553345	O
,	O
ethics	O
approval	O
06	O
/	O
MRE04	O
/	O
65	O
)	O
[	O
18	O
].	O

Collection	O
was	O
performed	O
at	O
initial	O
TURBT	O
,	O
prior	O
to	O
adjuvant	O
treatment	O
,	O
as	O
previously	O
described	O
[	O
18	O
].	O

Patients	O
provided	O
informed	O
written	O
consent	O
to	O
have	O
data	O
from	O
their	O
medical	O
records	O
used	O
in	O
research	O
(	O
UK	O
Research	O
Ethics	O
Committee	O
approval	O
:	O
06	O
/	O
MRE04	O
/	O
65	O
).	O

Patient	O
demographic	O
information	O
is	O
presented	O
Table	O
A	O
in	O
S1	O
File	O
.	O

Immunohistochemistry	O

Full	O
description	O
of	O
immunohistochemistry	O
protocols	O
is	O
provided	O
in	O
S2	O
File	O
.	O

Briefly	O
,	O
after	O
de	O
-	O
waxing	O
and	O
antigen	O
retrieval	O
,	O
FFPE	O
bladder	B-DS
tumour	I-DS
sections	O
were	O
stained	O
with	O
a	O
range	O
of	O
antibodies	O
(	O
Table	O
A	O
in	O
S2	O
File	O
)	O
and	O
HRP	O
-	O
DAB	O
and	O
/	O
or	O
alkaline	B-GP
phosphatase	I-GP
-	O
vector	O
red	O
enzyme	O
-	O
substrate	O
combinations	O
(	O
Vector	O
,	O
UK	O
),	O
with	O
haematoxylin	O
(	O
Sigma	O
,	O
UK	O
)	O
counterstain	O
.	O

Images	O
are	O
at	O
x100	O
magnification	O
unless	O
otherwise	O
stated	O
.	O

Staining	O
quantification	O

Slides	O
were	O
assessed	O
by	O
a	O
qualified	O
pathologist	O
(	O
EC	O
),	O
blinded	O
to	O
the	O
hypothesis	O
being	O
tested	O
.	O

For	O
each	O
patient	O
,	O
numbers	O
of	O
positive	O
cells	O
in	O
10	O
high	O
power	O
fields	O
(	O
field	O
diameter	O
of	O
0	O
.	O
50mm	O
)	O
were	O
counted	O
.	O

Peritumour	O
was	O
defined	O
as	O
the	O
adjacent	O
area	O
within	O
one	O
high	O
power	O
field	O
from	O
the	O
tumour	B-DS
.	O

Stroma	O
was	O
defined	O
as	O
more	O
than	O
one	O
high	O
power	O
field	O
from	O
tumour	B-DS
.	O

Slides	O
that	O
did	O
not	O
contain	O
tumour	B-DS
were	O
omitted	O
.	O

Cell	O
lines	O
,	O
growth	O
and	O
migration	O
assays	O

Bladder	B-DS
cancer	I-DS
cell	O
lines	O
5637	O
and	O
HB	O
-	O
CLS	O
-	O
2	O
were	O
obtained	O
from	O
the	O
ATCC	O
.	O

EJ	O
cells	O
were	O
provided	O
by	O
Dr	O
.	O
N	O
.	O

Shimwell	O
,	O
University	O
of	O
Birmingham	O
.	O

The	O
breast	B-DS
cancer	I-DS
cell	O
line	O
MDA	O
-	O
MB	O
-	O
231	O
was	O
provided	O
by	O
Dr	O
.	O
R	O
.	O

Grand	O
,	O
University	O
of	O
Birmingham	O
.	O

Cell	O
lines	O
were	O
cultured	O
in	O
RPMI	O
-	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
foetal	O
bovine	O
serum	O
,	O
100	O
U	O
/	O
ml	O
penicillin	O
and	O
0	O
.	O
1	O
mg	O
/	O
ml	O
streptomycin	O
(	O
Sigma	O
);	O
mycoplasma	B-OG
testing	O
was	O
carried	O
out	O
on	O
receipt	O
and	O
at	O
regular	O
intervals	O
.	O

Recombinant	O
human	B-OG
IL	B-GP
-	I-GP
17A	I-GP
(	O
Peprotech	O
,	O
UK	O
)	O
was	O
added	O
as	O
described	O
.	O

Cell	O
growth	O
was	O
measured	O
following	O
5	O
day	O
culture	O
in	O
96	O
well	O
plates	O
using	O
WST	O
assay	O
(	O
Clontech	O
,	O
USA	O
).	O

Following	O
the	O
manufacturer	O
’	O
s	O
instructions	O
WST	O
was	O
added	O
and	O
assayed	O
after	O
2	O
hours	O
using	O
a	O
Wallac	O
Victor2	O
1420	O
Multilabel	O
counter	O
(	O
PerkinElmer	O
,	O
Italy	O
).	O

Cell	O
migration	O
was	O
measured	O
using	O
a	O
standard	O
wound	O
healing	O
assay	O
:	O
cells	O
in	O
triplicate	O
wells	O
of	O
a	O
24	O
well	O
plate	O
at	O
1x105	O
cells	O
/	O
well	O
with	O
rhIL	B-GP
-	I-GP
17	I-GP
added	O
for	O
48hrs	O
before	O
wounding	O
using	O
a	O
pipette	O
tip	O
.	O

Following	O
wounding	O
,	O
cells	O
were	O
washed	O
and	O
new	O
media	O
with	O
or	O
without	O
IL	B-GP
-	I-GP
17	I-GP
added	O
as	O
appropriate	O
.	O

Photographs	O
were	O
taken	O
at	O
0h	O
and	O
6h	O
post	O
-	O
wounding	O
and	O
the	O
area	O
of	O
the	O
wound	O
calculated	O
using	O
SPOT	O
Image	O
software	O
(	O
SPOT	O
Imaging	O
Solutions	O
,	O
USA	O
).	O

ELISA	O
and	O
flow	O
cytometry	O

IL	B-GP
-	I-GP
6	I-GP
and	O
IL	B-GP
-	I-GP
8	I-GP
were	O
measured	O
by	O
ELISA	O
(	O
BioLegend	O
UK	O
Ltd	O
)	O
following	O
the	O
manufacturer	O
’	O
s	O
protocol	O
.	O

Cell	O
surface	O
levels	O
of	O
the	O
IL	B-GP
-	I-GP
17	I-GP
receptor	I-GP
(	O
IL	B-GP
-	I-GP
17R	I-GP
)	O
were	O
measured	O
by	O
flow	O
cytometry	O
of	O
cells	O
stained	O
with	O
fluorophore	O
-	O
conjugated	O
IL	B-GP
-	I-GP
17R	I-GP
antibody	O
(	O
BioLegend	O
UK	O
Ltd	O
)	O
performed	O
on	O
an	O
Accuri	O
C6	O
flow	O
cytometer	O
(	O
BD	O
Biosciences	O
).	O

RNA	O
extraction	O
and	O
analysis	O

As	O
described	O
in	O
S2	O
File	O
,	O
cells	O
or	O
tissue	O
were	O
homogenised	O
in	O
Trizol	O
(	O
Invitrogen	O
)	O
and	O
isolated	O
with	O
an	O
RNeasy	O
kit	O
(	O
Qiagen	O
).	O

mRNA	O
was	O
quantified	O
by	O
q	O
-	O
RTPCR	O
using	O
Taqman	O
probes	O
(	O
Applied	O
Biosystems	O
)	O
listed	O
in	O
Table	O
C	O
in	O
S2	O
File	O
.	O

A	O
Human	B-OG
Genome	O
U133	O
Plus	O
2	O
.	O
0	O
Array	O
(	O
Affymetrix	O
)	O
was	O
used	O
to	O
assess	O
global	O
gene	O
expression	O
changes	O
in	O
EJ	O
or	O
5637	O
cells	O
untreated	O
or	O
treated	O
with	O
IL	B-GP
-	I-GP
17	I-GP
.	O

A	O
change	O
in	O
gene	O
expression	O
of	O
1	O
.	O
5	O
fold	O
was	O
used	O
to	O
dictate	O
inclusion	O
.	O

Statistical	O
analysis	O

Data	O
was	O
analysed	O
using	O
the	O
Graphpad	O
Prism	O
program	O
(	O
Graphpad	O
Software	O
Inc	O
.,	O
USA	O
).	O

Statistical	O
tests	O
used	O
are	O
detailed	O
for	O
each	O
result	O
.	O

For	O
survival	O
analysis	O
,	O
time	O
to	O
event	O
was	O
calculated	O
from	O
initial	O
registration	O
to	O
either	O
first	O
event	O
,	O
death	O
or	O
last	O
known	O
attendance	O
at	O
clinic	O
.	O

Results	O

The	O
immune	O
microenvironment	O
of	O
bladder	B-DS
cancer	I-DS

We	O
first	O
examined	O
the	O
frequency	O
of	O
immune	O
cells	O
present	O
in	O
the	O
microenvironment	O
of	O
UBC	B-DS
using	O
a	O
panel	O
of	O
antibodies	O
specific	O
for	O
markers	O
of	O
the	O
adaptive	O
,	O
(	O
CD3	B-GP
,	O
T	O
cells	O
;	O
FoxP3	B-GP
,	O
regulatory	O
T	O
cells	O
)	O
and	O
innate	O
(	O
TCRγ	B-GP
,	O
γδT	O
cells	O
;	O
CD15	B-GP
,	O
granulocytes	O
;	O
CD68	B-GP
,	O
macrophages	O
)	O
immune	O
responses	O
.	O

Representative	O
examples	O
of	O
this	O
analysis	O
are	O
shown	O
in	O
Fig	O
1	O
.	O

Infiltrates	O
of	O
CD3	B-GP
+	O
T	O
-	O
cells	O
were	O
mostly	O
present	O
in	O
lymphoid	O
aggregates	O
.	O

Lower	O
numbers	O
of	O
FoxP3	B-GP
+	O
cells	O
were	O
also	O
present	O
with	O
a	O
similar	O
distribution	O
.	O

In	O
contrast	O
,	O
no	O
γδT	O
-	O
cells	O
were	O
present	O
despite	O
reliably	O
detecting	O
these	O
cells	O
in	O
control	O
tonsillar	O
tissue	O
(	O
S1	O
Fig	O
).	O

In	O
keeping	O
with	O
previous	O
reports	O
[	O
14	O
],	O
large	O
numbers	O
of	O
CD68	B-GP
+	O
macrophage	O
were	O
present	O
and	O
these	O
were	O
more	O
widely	O
distributed	O
throughout	O
the	O
tumour	B-DS
than	O
T	O
cells	O
.	O

Interestingly	O
,	O
we	O
found	O
CD15	B-GP
+	O
granulocytes	O
present	O
within	O
the	O
bladder	B-DS
cancer	I-DS
microenvironment	O
with	O
a	O
similar	O
distribution	O
to	O
macrophages	O
.	O

Immunohistochemical	O
analysis	O
of	O
the	O
bladder	B-DS
cancer	I-DS
immune	O
microenvironment	O
.	O

Representative	O
results	O
from	O
bladder	B-DS
cancer	I-DS
FFPE	O
biopsy	O
sections	O
stained	O
using	O
primary	O
antibodies	O
specific	O
for	O
the	O
indicated	O
immune	O
cell	O
markers	O
.	O

Positive	O
cells	O
are	O
stained	O
with	O
DAB	O
(	O
brown	O
)	O
and	O
all	O
slides	O
are	O
counterstained	O
with	O
haematoxylin	O
(	O
blue	O
).	O

Negative	O
control	O
images	O
(	O
inset	O
)	O
were	O
obtained	O
by	O
substituting	O
an	O
isotype	O
control	O
antibody	O
for	O
the	O
primary	O
antibody	O
.	O
A	O
:	O
The	O
bladder	B-DS
cancer	I-DS
microenvironment	O
contains	O
CD3	B-GP
+	O
T	O
cells	O
,	O
FoxP3	B-GP
+	O
cells	O
,	O
CD68	B-GP
+	O
macrophages	O
and	O
CD15	B-GP
+	O
granulocytes	O
.	O
B	O
:	O
Representative	O
images	O
from	O
two	O
bladder	B-DS
cancer	I-DS
biopsies	O
with	O
high	O
(	O
left	O
)	O
or	O
low	O
(	O
right	O
)	O
numbers	O
of	O
IL	B-GP
-	I-GP
17	I-GP
positive	O
cells	O
present	O
.	O

Note	O
the	O
different	O
distributions	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
and	O
CD3	B-GP
+	O
cells	O
shown	O
in	O
A	O
.	O

An	O
antibody	O
specific	O
for	O
the	O
cytokine	B-GP
IL	B-GP
-	I-GP
17	I-GP
was	O
included	O
in	O
our	O
panel	O
.	O

This	O
cytokine	B-GP
is	O
widely	O
attributed	O
to	O
Th17	O
cells	O
,	O
a	O
subset	O
of	O
CD4	B-GP
+	O
T	O
cells	O
,	O
although	O
other	O
immune	O
cells	O
also	O
produce	O
IL	B-GP
-	I-GP
17	I-GP
[	O
19	O
].	O

Increased	O
numbers	O
of	O
Th17	O
cells	O
are	O
associated	O
with	O
both	O
improved	O
and	O
poorer	O
outcomes	O
dependent	O
on	O
the	O
disease	O
setting	O
[	O
20	O
–	O
24	O
].	O

IL	B-GP
-	I-GP
17	I-GP
has	O
been	O
implicated	O
in	O
the	O
response	O
to	O
BCG	B-OG
immunotherapy	O
in	O
a	O
murine	O
bladder	B-DS
cancer	I-DS
model	O
[	O
25	O
];	O
however	O
,	O
there	O
are	O
no	O
data	O
from	O
patients	O
as	O
to	O
the	O
role	O
of	O
IL	B-GP
-	I-GP
17	I-GP
in	O
UBC	B-DS
.	O

As	O
shown	O
in	O
Fig	O
1B	O
,	O
there	O
was	O
noticeable	O
variation	O
in	O
IL	B-GP
-	I-GP
17	I-GP
positive	O
(	O
IL	B-GP
-	I-GP
17	I-GP
+)	O
cells	O
in	O
different	O
tumour	B-DS
biopsies	O
.	O

When	O
present	O
,	O
the	O
majority	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
did	O
not	O
infiltrate	O
into	O
the	O
tumour	B-DS
but	O
were	O
located	O
in	O
the	O
tumour	B-DS
microenvironment	O
either	O
peritumorally	O
or	O
in	O
the	O
surrounding	O
tumour	B-DS
stroma	O
.	O

IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
are	O
increased	O
in	O
carcinoma	B-DS
in	I-DS
situ	I-DS

The	O
marked	O
differences	O
observed	O
in	O
the	O
frequency	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cell	O
infiltrate	O
led	O
us	O
to	O
stain	O
more	O
tumour	B-DS
specimens	O
(	O
n	O
=	O
48	O
).	O

All	O
biopsy	O
samples	O
with	O
elevated	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
were	O
from	O
patients	O
with	O
concomitant	O
CIS	B-DS
;	O
therefore	O
,	O
we	O
expanded	O
our	O
analysis	O
to	O
include	O
further	O
CIS	B-DS
patients	O
(	O
n	O
=	O
83	O
).	O

Regarding	O
all	O
patients	O
,	O
all	O
but	O
one	O
sample	O
with	O
elevated	O
numbers	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
were	O
from	O
grade	O
3	O
tumours	B-DS
;	O
however	O
,	O
not	O
all	O
grade	O
3	O
tumours	B-DS
had	O
elevated	O
numbers	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
(	O
Fig	O
2A	O
).	O

Examining	O
the	O
stage	O
of	O
the	O
tumours	B-DS
at	O
time	O
of	O
diagnosis	O
demonstrated	O
that	O
there	O
was	O
a	O
significant	O
increase	O
in	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
in	O
CIS	B-DS
patients	O
(	O
p	O
=	O
<	O
0	O
.	O
0001	O
),	O
although	O
not	O
all	O
CIS	B-DS
patients	O
have	O
enhanced	O
levels	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
(	O
Fig	O
2B	O
).	O

Association	O
between	O
IL	B-GP
-	I-GP
17	I-GP
positive	O
cells	O
and	O
bladder	B-DS
cancer	I-DS
grade	O
and	O
stage	O
.	O

Upper	O
panels	O
:	O
The	O
number	O
of	O
IL	B-GP
-	I-GP
17	I-GP
positive	O
cells	O
present	O
in	O
different	O
bladder	B-DS
cancer	I-DS
biopsies	O
are	O
displayed	O
according	O
to	O
(	O
A	O
)	O
grade	O
at	O
time	O
of	O
diagnosis	O
(	O
G1	O
,	O
n	O
=	O
10	O
;	O
G2	O
,	O
n	O
=	O
9	O
;	O
G3	O
n	O
=	O
95	O
)	O
or	O
(	O
B	O
)	O
stage	O
at	O
time	O
of	O
diagnosis	O
(	O
pTa	O
,	O
n	O
=	O
17	O
;	O
pT1	O
,	O
n	O
=	O
10	O
;	O
T2	O
+,	O
n	O
=	O
8	O
;	O
CIS	B-DS
,	O
n	O
=	O
83	O
).	O

Horizontal	O
bars	O
indicate	O
the	O
mean	O
number	O
of	O
cells	O
present	O
in	O
all	O
biopsies	O
within	O
each	O
subgroup	O
.	O
Lower	O
panels	O
:	O
Results	O
of	O
quantitative	O
rtPCR	O
measuring	O
RNA	O
transcripts	O
present	O
in	O
whole	O
snap	O
frozen	O
biopsies	O
diagnosed	O
as	O
stage	O
pTa	O
/	O
pT1	O
(	O
n	O
=	O
5	O
)	O
or	O
pTa	O
/	O
pT1	O
with	O
concomitant	O
CIS	B-DS
(	O
n	O
=	O
3	O
).	O

The	O
ΔCT	O
values	O
of	O
mRNA	O
transcripts	O
of	O
(	O
C	O
)	O
IL	B-GP
-	I-GP
17A	I-GP
,	O
(	O
D	O
)	O
IL	B-GP
-	I-GP
17	I-GP
-	I-GP
F	I-GP
,	O
(	O
E	O
)	O
IL	B-GP
-	I-GP
6	I-GP
or	O
(	O
F	O
)	O
IL	B-GP
-	I-GP
23	I-GP
are	O
shown	O
relative	O
to	O
GAPDH	B-GP
(	O
ΔCT	O
=	O
CTExperimental	O
-	O
CTGAPDH	B-GP
).	O

Asterisks	O
indicate	O
significance	O
calculated	O
by	O
one	O
way	O
ANOVA	O
with	O
Dunn	O
’	O
s	O
multiple	O
comparison	O
test	O
(	O
B	O
)	O
or	O
unpaired	O
T	O
-	O
test	O
(	O
C	O
-	O
F	O
):	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
,	O
****	O
p	O
<	O
0	O
.	O
0001	O
,	O
n	O
/	O
s	O
=	O
not	O
significant	O
.	O

We	O
next	O
performed	O
qRT	O
-	O
PCR	O
to	O
confirm	O
that	O
the	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
detected	O
in	O
CIS	B-DS
biopsies	O
were	O
expressing	O
the	O
cytokine	B-GP
in	O
situ	O
.	O

Ideally	O
,	O
qRT	O
-	O
PCR	O
would	O
have	O
been	O
performed	O
after	O
isolating	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
by	O
laser	O
capture	O
microdissection	O
,	O
allowing	O
the	O
transcriptome	O
of	O
the	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
to	O
be	O
examined	O
.	O

Unfortunately	O
,	O
no	O
useable	O
RNA	O
could	O
be	O
extracted	O
from	O
microdissected	O
cells	O
after	O
IL	B-GP
-	I-GP
17	I-GP
staining	O
.	O

We	O
therefore	O
obtained	O
whole	O
tumour	B-DS
biopsy	O
RNA	O
from	O
patients	O
with	O
NIMBC	B-DS
grade	O
3	O
disease	O
with	O
or	O
without	O
concomitant	O
CIS	B-DS
and	O
examined	O
gene	O
expression	O
in	O
the	O
total	O
tumour	B-DS
microenvironment	O
.	O

Even	O
though	O
tumour	B-DS
and	O
stromal	O
cells	O
were	O
present	O
in	O
excess	O
,	O
we	O
detected	O
increased	O
IL	B-GP
-	I-GP
17	I-GP
mRNA	O
transcripts	O
in	O
samples	O
from	O
patients	O
with	O
CIS	B-DS
(	O
Fig	O
2C	O
),	O
concordant	O
with	O
the	O
staining	O
data	O
,	O
although	O
these	O
data	O
did	O
not	O
reach	O
significance	O
.	O

Examining	O
transcripts	O
related	O
to	O
and	O
downstream	O
of	O
IL	B-GP
-	I-GP
17	I-GP
,	O
we	O
similarly	O
measured	O
increased	O
mRNA	O
levels	O
of	O
the	O
related	O
cytokine	B-GP
IL	B-GP
-	I-GP
17F	I-GP
as	O
well	O
as	O
IL	B-GP
-	I-GP
6	I-GP
,	O
the	O
expression	O
of	O
which	O
is	O
upregulated	O
by	O
IL	B-GP
-	I-GP
17	I-GP
[	O
26	O
]	O
(	O
Fig	O
2D	O
and	O
2E	O
).	O

Interestingly	O
,	O
there	O
was	O
no	O
difference	O
in	O
levels	O
of	O
IL	B-GP
-	I-GP
23	I-GP
mRNA	O
,	O
a	O
cytokine	B-GP
that	O
promotes	O
IL	B-GP
-	I-GP
17	I-GP
secretion	O
and	O
maintains	O
Th17	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
[	O
27	O
,	O
28	O
].	O

Direct	O
effects	O
of	O
IL	B-GP
-	I-GP
17	I-GP
on	O
bladder	B-DS
cancer	I-DS
cells	O
in	O
vitro	O

We	O
next	O
considered	O
the	O
potential	O
biological	O
consequences	O
of	O
elevated	O
numbers	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
.	O

IL	B-GP
-	I-GP
17	I-GP
has	O
been	O
reported	O
to	O
act	O
directly	O
on	O
tumour	B-DS
and	O
stromal	O
cells	O
that	O
express	O
the	O
IL	B-GP
-	I-GP
17	I-GP
receptor	I-GP
(	O
IL	B-GP
-	I-GP
17R	I-GP
).	O

To	O
our	O
knowledge	O
IL	B-GP
-	I-GP
17R	I-GP
expression	O
had	O
not	O
been	O
examined	O
in	O
UBC	B-DS
and	O
,	O
consequently	O
,	O
the	O
potential	O
direct	O
effects	O
of	O
IL	B-GP
-	I-GP
17	I-GP
were	O
unknown	O
.	O

We	O
therefore	O
undertook	O
two	O
sets	O
of	O
experiments	O
to	O
determine	O
the	O
effect	O
of	O
elevated	O
IL	B-GP
-	I-GP
17	I-GP
on	O
bladder	B-DS
tumours	I-DS
.	O

First	O
,	O
we	O
stained	O
14	O
bladder	B-DS
cancer	I-DS
biopsies	O
(	O
randomly	O
selected	O
to	O
represent	O
different	O
disease	O
stages	O
)	O
with	O
an	O
IL	B-GP
-	I-GP
17R	I-GP
-	O
specific	O
antibody	O
.	O

All	O
were	O
positive	O
for	O
IL	B-GP
-	I-GP
17R	I-GP
irrespective	O
of	O
the	O
tumour	B-DS
grade	O
or	O
stage	O
(	O
Fig	O
3A	O
);	O
this	O
finding	O
was	O
subsequently	O
confirmed	O
by	O
others	O
during	O
the	O
preparation	O
of	O
this	O
manuscript	O
[	O
29	O
].	O

Next	O
,	O
we	O
examined	O
the	O
direct	O
effect	O
of	O
IL	B-GP
-	I-GP
17	I-GP
on	O
three	O
bladder	B-DS
cancer	I-DS
cell	O
lines	O
(	O
EJ	O
,	O
5637	O
and	O
HB	O
-	O
CLS	O
-	O
2	O
)	O
all	O
of	O
which	O
expressed	O
IL	B-GP
-	I-GP
17R	I-GP
at	O
the	O
same	O
level	O
(	O
Fig	O
3B	O
).	O

All	O
three	O
bladder	B-DS
cancer	I-DS
cell	O
lines	O
were	O
responsive	O
to	O
IL	B-GP
-	I-GP
17	I-GP
,	O
as	O
demonstrated	O
by	O
increased	O
production	O
of	O
IL	B-GP
-	I-GP
6	I-GP
and	O
IL	B-GP
-	I-GP
8	I-GP
(	O
Fig	O
3C	O
and	O
3D	O
).	O

However	O
,	O
subsequent	O
experiments	O
revealed	O
marked	O
differences	O
in	O
the	O
way	O
these	O
cell	O
lines	O
responded	O
to	O
IL	B-GP
-	I-GP
17	I-GP
:	O
growth	O
of	O
5637	O
cells	O
was	O
increased	O
by	O
IL	B-GP
-	I-GP
17	I-GP
in	O
a	O
dose	O
dependent	O
manner	O
,	O
yet	O
in	O
the	O
same	O
experiments	O
growth	O
of	O
EJ	O
or	O
HB	O
-	O
CLS	O
-	O
2	O
cells	O
was	O
not	O
significantly	O
altered	O
(	O
Fig	O
3E	O
).	O

A	O
similar	O
pattern	O
of	O
results	O
was	O
seen	O
in	O
wound	O
healing	O
assays	O
with	O
5637	O
cells	O
showing	O
a	O
significant	O
response	O
to	O
IL	B-GP
-	I-GP
17	I-GP
resulting	O
in	O
decreased	O
migration	O
,	O
while	O
EJ	O
and	O
HB	O
-	O
CLS	O
-	O
2	O
cells	O
were	O
unaffected	O
(	O
Fig	O
3F	O
).	O

These	O
findings	O
are	O
in	O
contrast	O
to	O
previous	O
work	O
on	O
other	O
cancer	B-DS
cell	O
lines	O
showing	O
IL	B-GP
-	I-GP
17	I-GP
to	O
enhance	O
cell	O
migration	O
[	O
24	O
],	O
as	O
demonstrated	O
by	O
the	O
breast	B-DS
cancer	I-DS
control	O
cell	O
line	O
included	O
in	O
our	O
experiments	O
(	O
MDA	O
-	O
MB	O
-	O
231	O
).	O

IL	B-GP
-	I-GP
17	I-GP
receptor	I-GP
expression	O
and	O
function	O
in	O
bladder	B-DS
cancer	I-DS
.	O

A	O
:	O
Representative	O
result	O
obtained	O
for	O
a	O
bladder	B-DS
cancer	I-DS
biopsy	O
,	O
in	O
this	O
case	O
CIS	B-DS
,	O
stained	O
with	O
a	O
primary	O
antibody	O
specific	O
for	O
the	O
IL	B-GP
-	I-GP
17	I-GP
receptor	I-GP
(	O
brown	O
staining	O
represents	O
receptor	O
expression	O
).	O

Inset	O
image	O
shows	O
result	O
obtained	O
using	O
an	O
isotype	O
control	O
primary	O
antibody	O
.	O
B	O
:	O
Histograms	O
showing	O
levels	O
of	O
IL	B-GP
-	I-GP
17	I-GP
receptor	I-GP
on	O
surface	O
of	O
the	O
urothelial	O
cell	O
lines	O
EJ	O
,	O
5637	O
or	O
HB	O
-	O
CLS	O
-	O
2	O
measured	O
using	O
flow	O
cytometry	O
.	O

Red	O
histogram	O
,	O
anti	O
-	O
IL	B-GP
-	I-GP
17	I-GP
-	I-GP
receptor	I-GP
antibody	O
;	O
open	O
histogram	O
,	O
isotype	O
control	O
antibody	O
.	O
C	O
&	O
D	O
:	O
IL	B-GP
-	I-GP
17	I-GP
treatment	O
increases	O
production	O
of	O
IL	B-GP
-	I-GP
6	I-GP
and	O
IL	B-GP
-	I-GP
8	I-GP
by	O
all	O
three	O
urothelial	O
cell	O
lines	O
tested	O
.	O

Cytokine	B-GP
levels	O
were	O
measured	O
by	O
ELISA	O
.	O

Error	O
bars	O
represent	O
the	O
standard	O
deviation	O
of	O
the	O
mean	O
,	O
which	O
was	O
calculated	O
from	O
three	O
(	O
IL	B-GP
-	I-GP
6	I-GP
)	O
or	O
four	O
(	O
IL	B-GP
-	I-GP
8	I-GP
)	O
independent	O
experiments	O
.	O

Asterisks	O
indicate	O
significance	O
calculated	O
by	O
repeated	O
measure	O
ANOVA	O
with	O
Bonferroni	O
multiple	O
comparison	O
test	O
:	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
,	O
***	O
p	O
<	O
0	O
.	O
001	O
..	O

E	O
:	O
Growth	O
of	O
EJ	O
,	O
5637	O
and	O
HB	O
-	O
CLS	O
-	O
2	O
cells	O
after	O
five	O
days	O
incubation	O
in	O
the	O
indicated	O
amounts	O
of	O
IL	B-GP
-	I-GP
17	I-GP
.	O

Cell	O
growth	O
was	O
measured	O
by	O
WST	O
assay	O
.	O

Four	O
independent	O
experiments	O
were	O
performed	O
and	O
the	O
mean	O
change	O
in	O
WST	O
-	O
1	O
absorbance	O
relative	O
to	O
mock	O
treated	O
cells	O
is	O
shown	O
.	O

Error	O
bars	O
indicate	O
standard	O
deviation	O
.	O
F	O
:	O
Migration	O
of	O
the	O
above	O
cells	O
in	O
a	O
6	O
hour	O
wound	O
healing	O
assay	O
in	O
the	O
absence	O
or	O
presence	O
of	O
the	O
indicated	O
concentrations	O
of	O
IL	B-GP
-	I-GP
17	I-GP
.	O

Cells	O
were	O
grown	O
in	O
IL	B-GP
-	I-GP
17	I-GP
for	O
48	O
hours	O
before	O
wounding	O
.	O

The	O
breast	B-DS
cancer	I-DS
cell	O
line	O
MBA	O
-	O
MD231	O
,	O
which	O
is	O
more	O
invasive	O
in	O
response	O
to	O
IL	B-GP
-	I-GP
17	I-GP
,	O
was	O
included	O
as	O
a	O
positive	O
control	O
.	O

Three	O
independent	O
experiments	O
were	O
performed	O
and	O
the	O
mean	O
wound	O
closure	O
is	O
shown	O
,	O
error	O
bars	O
represent	O
standard	O
deviation	O
.	O

In	O
both	O
panels	O
:	O
*	O
p	O
<	O
0	O
.	O
05	O
calculated	O
by	O
a	O
repeated	O
measure	O
ANOVA	O
with	O
Bonferroni	O
multiple	O
comparison	O
test	O
.	O
G	O
:	O
Venn	O
diagrams	O
showing	O
gene	O
expression	O
changes	O
induced	O
by	O
IL	B-GP
-	I-GP
17	I-GP
treatment	O
of	O
EJ	O
cells	O
(	O
light	O
grey	O
circles	O
)	O
or	O
5637	O
cells	O
(	O
dark	O
grey	O
circles	O
)	O
measured	O
in	O
a	O
gene	O
array	O
.	O

The	O
number	O
of	O
genes	O
that	O
undergo	O
similar	O
changes	O
in	O
expression	O
following	O
IL	B-GP
-	I-GP
17	I-GP
treatment	O
are	O
shown	O
in	O
the	O
intersect	O
,	O
and	O
are	O
also	O
listed	O
below	O
each	O
Venn	O
diagram	O
.	O

Direct	O
effects	O
of	O
IL	B-GP
-	I-GP
17	I-GP
on	O
gene	O
expression	O
in	O
vitro	O

The	O
marked	O
differences	O
in	O
phenotype	O
exhibited	O
by	O
different	O
bladder	B-DS
cancer	I-DS
cell	O
lines	O
exposed	O
to	O
IL	B-GP
-	I-GP
17	I-GP
led	O
us	O
to	O
perform	O
microarray	O
analysis	O
to	O
examine	O
the	O
effects	O
of	O
IL	B-GP
-	I-GP
17	I-GP
on	O
global	O
gene	O
expression	O
.	O

The	O
5637	O
and	O
EJ	O
cells	O
that	O
demonstrated	O
contrasting	O
behaviour	O
in	O
the	O
functional	O
assays	O
above	O
were	O
either	O
treated	O
or	O
untreated	O
with	O
IL	B-GP
-	I-GP
17	I-GP
as	O
before	O
and	O
changes	O
in	O
gene	O
expression	O
were	O
analysed	O
.	O

Both	O
cell	O
lines	O
responded	O
to	O
IL	B-GP
-	I-GP
17	I-GP
but	O
with	O
notably	O
different	O
changes	O
in	O
gene	O
expression	O
(	O
Fig	O
3G	O
).	O

Thus	O
,	O
for	O
5637	O
cells	O
448	O
genes	O
was	O
altered	O
by	O
IL	B-GP
-	I-GP
17	I-GP
(	O
249	O
upregulated	O
,	O
199	O
downregulated	O
)	O
and	O
105	O
genes	O
were	O
altered	O
for	O
EJ	O
cells	O
(	O
54	O
upregulated	O
and	O
51	O
downregulated	O
).	O

Comparing	O
both	O
cell	O
lines	O
,	O
only	O
12	O
genes	O
were	O
altered	O
in	O
the	O
same	O
way	O
by	O
IL	B-GP
-	I-GP
17	I-GP
(	O
5	O
upregulated	O
,	O
7	O
downregulated	O
).	O

One	O
of	O
the	O
upregulated	O
genes	O
was	O
IL	B-GP
-	I-GP
8	I-GP
,	O
the	O
increased	O
production	O
of	O
which	O
had	O
been	O
observed	O
earlier	O
following	O
IL	B-GP
-	I-GP
17	I-GP
treatment	O
(	O
Fig	O
3D	O
).	O

Furthermore	O
,	O
in	O
agreement	O
with	O
earlier	O
experiments	O
,	O
the	O
data	O
showed	O
IL	B-GP
-	I-GP
17	I-GP
to	O
increase	O
expression	O
of	O
IL	B-GP
-	I-GP
6	I-GP
in	O
both	O
cell	O
lines	O
;	O
this	O
gene	O
was	O
not	O
included	O
as	O
one	O
of	O
the	O
upregulated	O
genes	O
because	O
although	O
the	O
increase	O
in	O
EJ	O
cells	O
(	O
1	O
.	O
93	O
fold	O
increase	O
)	O
was	O
above	O
the	O
pre	O
-	O
defined	O
1	O
.	O
5	O
-	O
fold	O
cut	O
-	O
off	O
used	O
to	O
score	O
response	O
,	O
the	O
increase	O
for	O
5637	O
cells	O
fell	O
marginally	O
below	O
(	O
1	O
.	O
38	O
fold	O
increase	O
).	O

We	O
performed	O
cluster	O
analysis	O
on	O
the	O
genes	O
that	O
were	O
upregulated	O
in	O
5637	O
cells	O
by	O
IL	B-GP
-	I-GP
17	I-GP
(	O
Table	O
B	O
in	O
S1	O
File	O
).	O

Genes	O
associated	O
with	O
growth	O
factor	O
activity	O
were	O
increased	O
and	O
significantly	O
enriched	O
(	O
a	O
result	O
in	O
-	O
keeping	O
with	O
the	O
increased	O
growth	O
of	O
these	O
cells	O
following	O
IL	B-GP
-	I-GP
17	I-GP
treatment	O
);	O
genes	O
involved	O
in	O
angiogenesis	O
were	O
also	O
upregulated	O
by	O
treatment	O
with	O
IL	B-GP
-	I-GP
17	I-GP
.	O

In	O
contrast	O
,	O
genes	O
involved	O
in	O
the	O
inflammatory	O
response	O
and	O
cell	O
adhesion	O
were	O
downregulated	O
by	O
IL	B-GP
-	I-GP
17	I-GP
treatment	O
.	O

Mast	O
cells	O
constitute	O
the	O
majority	O
of	O
IL	B-GP
-	I-GP
17	I-GP
expressing	O
cells	O
in	O
CIS	B-DS

The	O
Th17	O
subset	O
of	O
CD4	B-GP
+	O
T	O
cells	O
are	O
recognised	O
as	O
important	O
producers	O
of	O
IL	B-GP
-	I-GP
17	I-GP
,	O
although	O
other	O
immune	O
cells	O
also	O
produce	O
IL	B-GP
-	I-GP
17	I-GP
[	O
26	O
].	O

Two	O
observations	O
suggested	O
that	O
the	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
present	O
in	O
CIS	B-DS
samples	O
were	O
not	O
CD4	B-GP
+	O
Th17	O
cells	O
.	O

First	O
,	O
the	O
morphology	O
of	O
the	O
cells	O
staining	O
positive	O
for	O
IL	B-GP
-	I-GP
17	I-GP
in	O
the	O
biopsies	O
did	O
not	O
appear	O
to	O
be	O
lymphocytic	O
.	O

Second	O
,	O
we	O
noted	O
the	O
general	O
localisation	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
was	O
different	O
to	O
CD3	B-GP
+	O
cells	O
in	O
serial	O
sections	O
from	O
the	O
same	O
CIS	B-DS
biopsy	O
(	O
Fig	O
1	O
).	O

To	O
identify	O
the	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cell	O
type	O
in	O
bladder	B-DS
CIS	I-DS
,	O
we	O
optimised	O
the	O
immunostaining	O
protocols	O
to	O
allow	O
FFPE	O
biopsies	O
to	O
be	O
stained	O
for	O
IL	B-GP
-	I-GP
17	I-GP
and	O
co	O
-	O
stained	O
for	O
CD3	B-GP
(	O
to	O
identify	O
T	O
cell	O
subsets	O
),	O
CD68	B-GP
(	O
to	O
identify	O
macrophages	O
)	O
or	O
CD15	B-GP
(	O
to	O
identify	O
granulocytes	O
).	O

As	O
expected	O
,	O
we	O
did	O
not	O
see	O
significant	O
co	O
-	O
localisation	O
of	O
IL	B-GP
-	I-GP
17	I-GP
with	O
CD3	B-GP
,	O
nor	O
did	O
we	O
see	O
co	O
-	O
localisation	O
with	O
CD68	B-GP
(	O
Fig	O
4A	O
).	O

However	O
,	O
the	O
majority	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
were	O
also	O
positive	O
for	O
CD15	B-GP
(	O
Fig	O
4A	O
and	O
4B	O
),	O
a	O
molecule	O
present	O
on	O
the	O
surface	O
of	O
all	O
granulocytes	O
including	O
neutrophils	O
,	O
mast	O
cells	O
(	O
MC	O
)	O
and	O
a	O
subset	O
of	O
myeloid	O
derived	O
suppressor	O
cells	O
(	O
MDSCs	O
).	O

Because	O
these	O
3	O
cell	O
types	O
have	O
each	O
been	O
reported	O
to	O
produce	O
IL	B-GP
-	I-GP
17	I-GP
[	O
26	O
]	O
we	O
stained	O
sections	O
for	O
specific	O
markers	O
of	O
neutrophils	O
(	O
ELANE	B-GP
)	O
or	O
MCs	O
(	O
mast	B-GP
cell	I-GP
tryptase	I-GP
,	O
MCT	B-GP
).	O

We	O
saw	O
little	O
or	O
no	O
ELANE	B-GP
staining	O
but	O
large	O
numbers	O
of	O
MCT	B-GP
-	O
positive	O
cells	O
were	O
present	O
(	O
Fig	O
4C	O
and	O
S2	O
Fig	O
).	O

To	O
formally	O
show	O
that	O
the	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
were	O
indeed	O
MCs	O
,	O
we	O
undertook	O
a	O
final	O
series	O
of	O
co	O
-	O
immunostaining	O
experiments	O
.	O

Immunostaining	O
of	O
IL	B-GP
-	I-GP
17	I-GP
was	O
predominantly	O
lost	O
when	O
sections	O
were	O
co	O
-	O
immunostained	O
for	O
MCT	B-GP
(	O
Fig	O
4D	O
),	O
consistent	O
with	O
strong	O
cytoplasmic	O
MCT	B-GP
staining	O
masking	O
the	O
IL	B-GP
-	I-GP
17	I-GP
signal	O
.	O

Interestingly	O
,	O
a	O
small	O
number	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
could	O
still	O
be	O
observed	O
on	O
these	O
slides	O
,	O
suggesting	O
that	O
the	O
biopsies	O
contained	O
a	O
small	O
number	O
of	O
non	O
-	O
MCs	O
that	O
also	O
produced	O
IL	B-GP
-	I-GP
17	I-GP
.	O

To	O
formally	O
demonstrate	O
IL	B-GP
-	I-GP
17	I-GP
and	O
MCT	B-GP
co	O
-	O
localisation	O
we	O
repeated	O
the	O
co	O
-	O
immunostaining	O
experiments	O
,	O
modifying	O
the	O
protocol	O
to	O
reduce	O
the	O
intensity	O
of	O
MCT	B-GP
staining	O
.	O

As	O
shown	O
in	O
Fig	O
4E	O
,	O
cells	O
positive	O
for	O
both	O
MCT	B-GP
and	O
IL	B-GP
-	I-GP
17	I-GP
were	O
observed	O
in	O
all	O
cases	O
confirming	O
that	O
MCs	O
are	O
the	O
main	O
source	O
of	O
IL	B-GP
-	I-GP
17	I-GP
in	O
the	O
tumour	B-DS
microenvironment	O
of	O
bladder	B-DS
CIS	I-DS
.	O

Identification	O
of	O
the	O
IL	B-GP
-	I-GP
17	I-GP
producing	O
cells	O
present	O
in	O
CIS	B-DS
.	O

A	O
:	O
Representative	O
results	O
of	O
co	O
-	O
staining	O
for	O
IL	B-GP
-	I-GP
17	I-GP
and	O
cell	O
lineage	O
markers	O
(	O
combined	O
IF	O
and	O
bright	O
field	O
images	O
.	O

Red	O
fluorescence	O
indicates	O
IL	B-GP
-	I-GP
17	I-GP
and	O
brown	O
staining	O
indicates	O
CD3	B-GP
(	O
left	O
image	O
),	O
CD15	B-GP
(	O
middle	O
)	O
or	O
CD68	B-GP
(	O
right	O
image	O
).	O

Note	O
that	O
CD15	B-GP
and	O
IL	B-GP
-	I-GP
17	I-GP
co	O
-	O
localise	O
as	O
indicated	O
by	O
arrows	O
.	O
B	O
:	O
The	O
region	O
indicated	O
by	O
dashed	O
lines	O
in	O
the	O
IL	B-GP
-	I-GP
17	I-GP
/	O
CD15	B-GP
co	O
-	O
staining	O
image	O
above	O
is	O
magnified	O
and	O
shown	O
in	O
bright	O
field	O
(	O
left	O
),	O
IF	O
(	O
middle	O
)	O
or	O
combined	O
IF	O
/	O
bright	O
field	O
(	O
right	O
).	O

Arrows	O
indicate	O
the	O
location	O
of	O
co	O
-	O
staining	O
cells	O
visualised	O
in	O
the	O
combined	O
IF	O
/	O
bright	O
field	O
image	O
.	O
C	O
:	O
Characterising	O
the	O
CD15	B-GP
-	O
positive	O
cells	O
present	O
in	O
CIS	B-DS
.	O

Representative	O
staining	O
results	O
from	O
a	O
single	O
CIS	B-DS
biopsy	O
containing	O
a	O
large	O
number	O
of	O
CD15	B-GP
positive	O
granulocytes	O
(	O
left	O
panel	O
).	O

This	O
biopsy	O
also	O
contains	O
MCs	O
that	O
stain	O
positive	O
for	O
MC	B-GP
tryptase	I-GP
(	O
MCT	B-GP
).	O

No	O
ELANE	B-GP
-	O
positive	O
neutrophils	O
were	O
present	O
(	O
right	O
panel	O
).	O

In	O
each	O
image	O
positive	O
cells	O
are	O
stained	O
brown	O
.	O

The	O
total	O
number	O
of	O
biopsies	O
stained	O
for	O
CD15	B-GP
,	O
ELANE	B-GP
or	O
MCT	B-GP
were	O
15	O
,	O
18	O
and	O
12	O
respectively	O
.	O

The	O
inset	O
images	O
show	O
sections	O
stained	O
using	O
appropriate	O
isotype	O
control	O
primary	O
antibodies	O
.	O
D	O
:	O
Co	O
-	O
localisation	O
of	O
MCT	B-GP
and	O
IL	B-GP
-	I-GP
17	I-GP
staining	O
in	O
CIS	B-DS
biopsies	O
.	O

Upper	O
image	O
shows	O
the	O
result	O
obtained	O
for	O
a	O
CIS	B-DS
biopsy	O
co	O
-	O
stained	O
with	O
anti	O
-	O
IL	B-GP
-	I-GP
17	I-GP
and	O
anti	O
-	O
MCT	B-GP
antibodies	O
(	O
red	O
and	O
dark	O
brown	O
staining	O
respectively	O
).	O

Note	O
how	O
the	O
weaker	O
IL	B-GP
-	I-GP
17	I-GP
signal	O
is	O
obscured	O
by	O
the	O
dark	O
brown	O
staining	O
of	O
the	O
MCT	B-GP
-	O
positive	O
cells	O
.	O

Lower	O
image	O
shows	O
a	O
serial	O
section	O
from	O
the	O
same	O
tumour	B-DS
specimen	O
stained	O
for	O
IL	B-GP
-	I-GP
17	I-GP
alone	O
(	O
red	O
)	O
for	O
comparison	O
.	O

The	O
result	O
is	O
representative	O
of	O
eight	O
CIS	B-DS
biopsies	O
analysed	O
.	O
E	O
:	O
Result	O
of	O
co	O
-	O
staining	O
a	O
CIS	B-DS
biopsy	O
for	O
IL	B-GP
-	I-GP
17	I-GP
(	O
red	O
)	O
and	O
reduced	O
intensity	O
MCT	B-GP
(	O
brown	O
).	O

Arrows	O
indicate	O
MCT	B-GP
-	O
positive	O
MCs	O
that	O
co	O
-	O
stain	O
for	O
IL	B-GP
-	I-GP
17	I-GP
(	O
magnification	O
x1000	O
).	O

Image	O
is	O
representative	O
of	O
the	O
four	O
CIS	B-DS
biopsies	O
stained	O
using	O
the	O
modified	O
protocol	O
.	O

Elevated	O
numbers	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
correlate	O
with	O
improved	O
BCG	B-OG
response	O
in	O
CIS	B-DS

The	O
wide	O
variation	O
in	O
the	O
number	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
in	O
CIS	B-DS
specimens	O
(	O
Fig	O
2B	O
)	O
prompted	O
us	O
to	O
examine	O
whether	O
there	O
was	O
an	O
association	O
between	O
IL	B-GP
-	I-GP
17	I-GP
status	O
and	O
outcome	O
.	O

Patients	O
in	O
the	O
upper	O
quartile	O
of	O
IL	B-GP
-	I-GP
17	I-GP
positivity	O
(	O
above	O
374	O
.	O
5	O
cells	O
per	O
10	O
hpf	O
)	O
did	O
not	O
initially	O
seem	O
to	O
demonstrate	O
different	O
outcomes	O
to	O
the	O
remainder	O
(	O
Fig	O
5A	O
).	O

However	O
,	O
IL	B-GP
-	I-GP
17	I-GP
has	O
been	O
implicated	O
in	O
the	O
efficacy	O
of	O
BCG	B-OG
immunotherapy	O
in	O
a	O
murine	O
bladder	B-DS
cancer	I-DS
model	O
[	O
25	O
];	O
although	O
patients	O
with	O
high	O
grade	O
NMIBC	B-DS
should	O
be	O
offered	O
intravesical	O
BCG	B-OG
,	O
not	O
all	O
patients	O
actually	O
receive	O
this	O
treatment	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
outcome	O
of	O
patients	O
who	O
actually	O
received	O
intravesical	O
BCG	B-OG
(	O
n	O
=	O
41	O
,	O
Table	O
C	O
in	O
S1	O
File	O
).	O

Using	O
the	O
same	O
cut	O
-	O
off	O
to	O
divide	O
patients	O
into	O
IL	B-GP
-	I-GP
17	I-GP
high	O
and	O
low	O
(	O
above	O
or	O
below	O
374	O
.	O
5	O
cells	O
per	O
10	O
hpf	O
,	O
respectively	O
),	O
there	O
was	O
a	O
significant	O
difference	O
in	O
outcome	O
(	O
Fig	O
5B	O
):	O
patients	O
with	O
high	O
numbers	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
had	O
better	O
event	O
-	O
free	O
survival	O
(	O
p	O
=	O
0	O
.	O
0449	O
,	O
HR	O
0	O
.	O
2918	O
,	O
95	O
%	O
CI	O
0	O
.	O
08762	O
to	O
0	O
.	O
9721	O
)	O
when	O
treated	O
with	O
BCG	B-OG
.	O

These	O
data	O
strongly	O
suggest	O
that	O
the	O
presence	O
of	O
increased	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
(	O
the	O
majority	O
of	O
which	O
are	O
mast	O
cells	O
)	O
is	O
beneficial	O
for	O
NMIBC	B-DS
patients	O
with	O
concomitant	O
CIS	B-DS
when	O
receiving	O
intravesical	O
BCG	B-OG
.	O

The	O
effect	O
of	O
tumoral	O
IL	B-GP
-	I-GP
17	I-GP
positive	O
cells	O
upon	O
patient	O
outcome	O
.	O

A	O
:	O
Patients	O
who	O
had	O
NMIBCs	O
with	O
concomitant	O
CIS	B-DS
were	O
divided	O
into	O
IL	O
-	O
17hi	O
(	O
n	O
=	O
14	O
)	O
and	O
IL	O
-	O
17low	O
(	O
n	O
=	O
52	O
)	O
groups	O
based	O
on	O
the	O
upper	O
quartile	O
of	O
IL	B-GP
-	I-GP
17	I-GP
positive	O
cell	O
counts	O
in	O
this	O
group	O
of	O
patients	O
(	O
374	O
.	O
5	O
IL	B-GP
-	I-GP
17	I-GP
positive	O
cells	O
per	O
10	O
high	O
power	O
fields	O
).	O
B	O
:	O
Patients	O
who	O
received	O
BCG	B-OG
immunotherapy	O
were	O
divided	O
into	O
IL	O
-	O
17hi	O
(	O
n	O
=	O
6	O
)	O
and	O
IL	O
-	O
17lo	O
(	O
n	O
=	O
36	O
)	O
groups	O
,	O
using	O
the	O
same	O
criteria	O
as	O
before	O
.	O

Significance	O
was	O
calculated	O
using	O
the	O
Log	O
-	O
rank	O
(	O
Mantel	O
-	O
Cox	O
)	O
test	O
.	O

Dotted	O
line	O
indicates	O
95	O
%	O
CI	O
.	O

Discussion	O

The	O
tumour	B-DS
microenvironment	O
is	O
critically	O
important	O
in	O
the	O
development	O
,	O
progression	O
and	O
control	O
of	O
cancer	B-DS
[	O
11	O
].	O

Our	O
aim	O
was	O
to	O
further	O
understand	O
the	O
immune	O
microenvironment	O
of	O
UBC	B-DS
,	O
making	O
use	O
of	O
tumour	B-DS
samples	O
collected	O
at	O
the	O
time	O
of	O
diagnosis	O
,	O
prior	O
to	O
treatment	O
.	O

We	O
detected	O
a	O
diverse	O
infiltrate	O
of	O
innate	O
and	O
adaptive	O
immune	O
cells	O
including	O
macrophages	O
and	O
T	O
cells	O
(	O
which	O
have	O
been	O
described	O
by	O
others	O
[	O
14	O
,	O
30	O
]),	O
and	O
also	O
FoxP3	B-GP
+	O
Tregs	O
[	O
16	O
].	O

Interestingly	O
,	O
we	O
did	O
not	O
detect	O
infiltration	O
of	O
γδT	O
cells	O
,	O
a	O
cell	O
type	O
reported	O
to	O
inhibit	O
tumour	B-DS
growth	O
in	O
a	O
murine	O
orthotopic	O
bladder	B-DS
cancer	I-DS
model	O
[	O
25	O
].	O

The	O
most	O
novel	O
finding	O
was	O
the	O
marked	O
variation	O
in	O
the	O
numbers	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
between	O
different	O
patients	O
’	O
tumours	B-DS
,	O
with	O
increased	O
numbers	O
of	O
these	O
cells	O
significantly	O
associated	O
with	O
CIS	B-DS
.	O

However	O
,	O
we	O
also	O
observed	O
that	O
some	O
patients	O
with	O
CIS	B-DS
had	O
few	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
in	O
their	O
tumours	B-DS
,	O
suggesting	O
their	O
presence	O
was	O
more	O
complex	O
than	O
a	O
simple	O
causal	O
association	O
.	O

We	O
next	O
examined	O
the	O
identity	O
of	O
the	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
we	O
observed	O
in	O
CIS	B-DS
.	O

Based	O
on	O
their	O
appearance	O
,	O
frequency	O
and	O
distribution	O
within	O
the	O
tumour	B-DS
,	O
the	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
were	O
clearly	O
not	O
T	O
cells	O
.	O

Their	O
expression	O
of	O
CD15	B-GP
suggested	O
they	O
were	O
neutrophils	O
,	O
MDSCs	O
or	O
MCs	O
.	O

The	O
crucial	O
observation	O
that	O
almost	O
all	O
IL	B-GP
-	I-GP
17	I-GP
+	O
cells	O
co	O
-	O
localised	O
with	O
MCT	B-GP
,	O
a	O
highly	O
-	O
specific	O
MC	O
marker	O
,	O
highlighted	O
MCs	O
as	O
the	O
predominant	O
source	O
of	O
IL	B-GP
-	I-GP
17	I-GP
in	O
bladder	B-DS
CIS	I-DS
.	O

The	O
increased	O
frequency	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
MCs	O
in	O
CIS	B-DS
raised	O
the	O
question	O
of	O
their	O
role	O
.	O

MCs	O
have	O
been	O
reported	O
to	O
have	O
anti	O
-	O
tumour	B-DS
effects	O
,	O
modifying	O
anti	O
-	O
tumour	B-DS
immune	O
responses	O
and	O
enhancing	O
T	O
cell	O
recruitment	O
[	O
31	O
,	O
32	O
].	O

Conversely	O
,	O
MCs	O
enhance	O
tumorigenesis	O
and	O
angiogenesis	O
[	O
33	O
–	O
35	O
],	O
and	O
have	O
been	O
reported	O
to	O
inhibit	O
anti	O
-	O
tumour	B-DS
immunity	O
[	O
36	O
,	O
37	O
].	O

Likewise	O
,	O
the	O
role	O
of	O
IL	B-GP
-	I-GP
17	I-GP
in	O
cancer	B-DS
is	O
complex	O
.	O

In	O
IL	B-GP
-	I-GP
17	I-GP
knockout	O
mice	B-OG
some	O
tumours	B-DS
grow	O
more	O
rapidly	O
,	O
whilst	O
others	O
grow	O
more	O
slowly	O
,	O
suggesting	O
that	O
IL	B-GP
-	I-GP
17	I-GP
’	O
s	O
effects	O
are	O
context	O
dependent	O
[	O
38	O
].	O

This	O
is	O
borne	O
out	O
in	O
the	O
clinical	O
setting	O
with	O
reports	O
of	O
both	O
better	O
and	O
worse	O
outcomes	O
associated	O
with	O
increased	O
numbers	O
of	O
Th17	O
cells	O
[	O
20	O
,	O
22	O
,	O
39	O
–	O
41	O
].	O

To	O
our	O
knowledge	O
,	O
no	O
-	O
one	O
has	O
previously	O
studied	O
the	O
effects	O
on	O
outcome	O
in	O
the	O
UBC	B-DS
setting	O
.	O

Although	O
IL	B-GP
-	I-GP
17	I-GP
can	O
act	O
indirectly	O
(	O
for	O
example	O
,	O
promoting	O
tumour	B-DS
growth	O
by	O
altering	O
the	O
immune	O
microenvironment	O
[	O
21	O
]),	O
it	O
can	O
also	O
act	O
directly	O
upon	O
tumour	B-DS
cells	O
that	O
bear	O
IL	B-GP
-	I-GP
17R	I-GP
[	O
42	O
].	O

Since	O
we	O
found	O
that	O
IL	B-GP
-	I-GP
17R	I-GP
was	O
expressed	O
by	O
many	O
bladder	B-DS
tumours	I-DS
,	O
we	O
decided	O
to	O
focus	O
on	O
the	O
potential	O
direct	O
effects	O
of	O
IL	B-GP
-	I-GP
17	I-GP
on	O
bladder	B-DS
cancer	I-DS
cells	O
.	O

IL	B-GP
-	I-GP
17	I-GP
induced	O
differential	O
responses	O
,	O
demonstrated	O
by	O
the	O
specific	O
changes	O
in	O
phenotype	O
and	O
gene	O
expression	O
in	O
different	O
cell	O
lines	O
.	O

IL	B-GP
-	I-GP
17	I-GP
increased	O
the	O
growth	O
rate	O
of	O
5637	O
cells	O
,	O
concurring	O
with	O
previously	O
published	O
work	O
examining	O
the	O
MB49	O
murine	O
bladder	B-DS
cancer	I-DS
cell	O
in	O
mice	B-OG
[	O
42	O
].	O

Furthermore	O
,	O
IL	B-GP
-	I-GP
17	I-GP
treatment	O
of	O
5637	O
cells	O
increased	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
angiogenesis	O
and	O
decreased	O
the	O
expression	O
of	O
those	O
involved	O
in	O
cell	O
adhesion	O
.	O

The	O
former	O
could	O
potentially	O
contribute	O
to	O
increased	O
tumour	B-DS
growth	O
in	O
vivo	O
,	O
while	O
the	O
latter	O
is	O
consistent	O
with	O
CIS	B-DS
being	O
a	O
loosely	O
-	O
adherent	O
lesion	O
that	O
often	O
disseminates	O
by	O
the	O
shedding	O
and	O
re	O
-	O
implantation	O
of	O
cells	O
[	O
43	O
].	O

In	O
contrast	O
,	O
growth	O
of	O
the	O
other	O
two	O
bladder	B-DS
cancer	I-DS
cell	O
lines	O
that	O
we	O
studied	O
was	O
not	O
significantly	O
affected	O
by	O
IL	B-GP
-	I-GP
17	I-GP
,	O
despite	O
eliciting	O
a	O
response	O
by	O
increased	O
production	O
of	O
IL	B-GP
-	I-GP
6	I-GP
and	O
IL	B-GP
-	I-GP
8	I-GP
.	O

Gene	O
expression	O
analysis	O
revealed	O
that	O
the	O
5637	O
and	O
EJ	O
cell	O
lines	O
had	O
very	O
different	O
patterns	O
of	O
gene	O
expression	O
in	O
response	O
to	O
IL	B-GP
-	I-GP
17	I-GP
.	O

Taken	O
together	O
these	O
results	O
demonstrate	O
that	O
the	O
direct	O
effects	O
of	O
IL	B-GP
-	I-GP
17	I-GP
vary	O
markedly	O
,	O
even	O
within	O
the	O
context	O
of	O
a	O
single	O
tumour	B-DS
type	O
.	O

Although	O
these	O
in	O
vitro	O
effects	O
were	O
interesting	O
,	O
we	O
sought	O
to	O
identify	O
the	O
consequences	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
MCs	O
in	O
patients	O
by	O
utilising	O
the	O
long	O
-	O
term	O
outcome	O
data	O
linked	O
to	O
the	O
tumour	B-DS
samples	O
.	O

We	O
acknowledge	O
that	O
such	O
an	O
approach	O
cannot	O
directly	O
address	O
biological	O
mechanisms	O
of	O
action	O
,	O
but	O
we	O
argue	O
that	O
it	O
is	O
more	O
relevant	O
to	O
human	B-OG
health	O
since	O
it	O
takes	O
into	O
account	O
the	O
clinical	O
interventions	O
that	O
patients	O
undergo	O
.	O

As	O
IL	B-GP
-	I-GP
17	I-GP
+	O
MCs	O
were	O
significantly	O
associated	O
with	O
CIS	B-DS
,	O
a	O
lesion	O
with	O
a	O
poor	O
prognosis	O
,	O
we	O
anticipated	O
that	O
increased	O
numbers	O
of	O
these	O
cells	O
would	O
be	O
associated	O
with	O
poorer	O
outcome	O
,	O
an	O
association	O
recently	O
observed	O
in	O
gastric	B-DS
cancer	I-DS
[	O
23	O
].	O

Paradoxically	O
,	O
CIS	B-DS
patients	O
with	O
higher	O
numbers	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
MCs	O
had	O
significantly	O
longer	O
event	O
-	O
free	O
survival	O
following	O
intravesical	O
BCG	B-OG
treatment	O
than	O
patients	O
with	O
a	O
lower	O
number	O
of	O
cells	O
.	O

This	O
finding	O
is	O
in	O
-	O
keeping	O
with	O
a	O
recent	O
study	O
in	O
oesophageal	B-DS
squamous	I-DS
cell	I-DS
carcinoma	I-DS
where	O
IL	B-GP
-	I-GP
17	I-GP
+	O
MCs	O
were	O
also	O
identified	O
,	O
and	O
increased	O
numbers	O
significantly	O
associated	O
with	O
favourable	O
survival	O
[	O
44	O
].	O

In	O
our	O
study	O
,	O
we	O
only	O
observed	O
a	O
significant	O
effect	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
MCs	O
in	O
patients	O
who	O
underwent	O
intravesical	O
BCG	B-OG
treatment	O
.	O

The	O
significant	O
effect	O
that	O
we	O
observed	O
in	O
CIS	B-DS
is	O
seemingly	O
larger	O
than	O
the	O
survival	O
advantage	O
seen	O
in	O
oesophageal	B-DS
cancer	I-DS
[	O
44	O
];	O
one	O
possibility	O
,	O
therefore	O
,	O
is	O
that	O
BCG	B-OG
amplifies	O
the	O
beneficial	O
effects	O
associated	O
with	O
increased	O
numbers	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
MCs	O
.	O

Currently	O
,	O
we	O
can	O
only	O
speculate	O
as	O
to	O
why	O
some	O
cases	O
of	O
bladder	B-DS
CIS	I-DS
demonstrate	O
increased	O
numbers	O
of	O
IL	B-GP
-	I-GP
17	I-GP
+	O
MCs	O
and	O
others	O
do	O
not	O
.	O

One	O
possibility	O
may	O
be	O
differences	O
in	O
the	O
tumour	B-DS
microenvironment	O
.	O

MCs	O
enter	O
tissues	O
in	O
an	O
immature	O
form	O
,	O
maturing	O
in	O
response	O
to	O
local	O
stimuli	O
.	O

Reports	O
have	O
demonstrated	O
IL	B-GP
-	I-GP
17	I-GP
+	O
MCs	O
at	O
sites	O
of	O
active	O
inflammation	O
in	O
rheumatoid	B-DS
arthritis	I-DS
[	O
45	O
–	O
47	O
],	O
psoriasis	B-DS
[	O
48	O
]	O
and	O
atherosclerotic	B-DS
plaques	I-DS
[	O
49	O
].	O

Furthermore	O
,	O
inflammatory	O
mediators	O
have	O
been	O
shown	O
to	O
stimulate	O
IL	B-GP
-	I-GP
17	I-GP
production	O
from	O
purified	O
human	B-OG
MCs	O
in	O
vitro	O
[	O
45	O
].	O

Thus	O
,	O
the	O
microenvironment	O
of	O
CIS	B-DS
may	O
stimulate	O
MCs	O
to	O
produce	O
IL	B-GP
-	I-GP
17	I-GP
.	O

We	O
note	O
that	O
CIS	B-DS
biopsies	O
contain	O
both	O
IL	B-GP
-	I-GP
17	I-GP
+	O
and	O
IL	B-GP
-	I-GP
17	I-GP
-	O
MCs	O
.	O

The	O
latter	O
may	O
reflect	O
recent	O
immigrants	O
that	O
have	O
not	O
yet	O
developed	O
an	O
IL	B-GP
-	I-GP
17	I-GP
-	O
producing	O
phenotype	O
,	O
or	O
a	O
distinct	O
subtype	O
of	O
MCs	O
unresponsive	O
to	O
the	O
environmental	O
cues	O
that	O
stimulate	O
production	O
of	O
IL	B-GP
-	I-GP
17	I-GP
.	O

In	O
this	O
regard	O
,	O
mature	O
connective	O
tissue	O
MCs	O
,	O
but	O
not	O
immature	O
bone	O
-	O
marrow	O
-	O
derived	O
MCs	O
,	O
have	O
been	O
shown	O
to	O
produce	O
IL	B-GP
-	I-GP
17	I-GP
following	O
toll	B-GP
-	I-GP
like	I-GP
receptor	I-GP
-	I-GP
2	I-GP
ligation	O
[	O
50	O
].	O

Deeper	O
understanding	O
of	O
the	O
mechanisms	O
responsible	O
for	O
the	O
improved	O
clinical	O
outcomes	O
associated	O
with	O
IL	B-GP
-	I-GP
17	I-GP
+	O
MCs	O
and	O
BCG	B-OG
is	O
hampered	O
by	O
a	O
lack	O
of	O
a	O
suitable	O
CIS	B-DS
mouse	B-OG
model	O
[	O
51	O
,	O
52	O
],	O
and	O
fundamental	O
differences	O
between	O
mouse	B-OG
and	O
human	B-OG
MC	O
biology	O
.	O

Many	O
reports	O
show	O
IL	B-GP
-	I-GP
17	I-GP
production	O
by	O
human	B-OG
MCs	O
[	O
19	O
,	O
23	O
,	O
45	O
,	O
47	O
,	O
48	O
,	O
53	O
,	O
54	O
],	O
but	O
only	O
a	O
single	O
study	O
hitherto	O
detected	O
IL	B-GP
-	I-GP
17	I-GP
+	O
murine	O
MCs	O
,	O
and	O
this	O
required	O
culture	O
of	O
the	O
cells	O
in	O
vitro	O
[	O
50	O
].	O

Other	O
studies	O
suggest	O
γδT	O
cells	O
produce	O
IL	B-GP
-	I-GP
17	I-GP
in	O
place	O
of	O
murine	O
MCs	O
[	O
19	O
];	O
consistently	O
,	O
γδT	O
cells	O
produce	O
IL	B-GP
-	I-GP
17	I-GP
in	O
response	O
to	O
BCG	B-OG
in	O
a	O
murine	O
model	O
of	O
bladder	B-DS
cancer	I-DS
[	O
25	O
].	O

In	O
this	O
model	O
,	O
IL	B-GP
-	I-GP
17	I-GP
was	O
required	O
for	O
BCG	B-OG
efficacy	O
through	O
IL	B-GP
-	I-GP
8	I-GP
production	O
and	O
increased	O
neutrophil	O
recruitment	O
,	O
in	O
keeping	O
with	O
clinical	O
data	O
showing	O
increased	O
IL	B-GP
-	I-GP
8	I-GP
,	O
within	O
the	O
first	O
few	O
hours	O
of	O
BCG	B-OG
treatment	O
is	O
predictive	O
of	O
response	O
[	O
12	O
,	O
55	O
,	O
56	O
].	O

Since	O
we	O
have	O
shown	O
an	O
absence	O
of	O
γδT	O
cells	O
in	O
human	B-OG
bladder	B-DS
tumours	I-DS
,	O
we	O
propose	O
an	O
alternative	O
scenario	O
in	O
humans	B-OG
.	O

We	O
suggest	O
that	O
the	O
immediate	O
response	O
to	O
BCG	B-OG
is	O
elicited	O
via	O
MCs	O
rapidly	O
releasing	O
IL	B-GP
-	I-GP
17	I-GP
,	O
inducing	O
IL	B-GP
-	I-GP
8	I-GP
production	O
by	O
urothelium	O
and	O
,	O
as	O
we	O
have	O
shown	O
,	O
tumour	B-DS
cells	O
recruiting	O
increased	O
numbers	O
of	O
neutrophils	O
.	O

It	O
could	O
then	O
be	O
envisioned	O
that	O
other	O
immune	O
cells	O
,	O
including	O
γδT	O
cells	O
,	O
will	O
then	O
be	O
recruited	O
,	O
eliciting	O
an	O
improved	O
immune	O
response	O
(	O
Fig	O
6	O
).	O

Proposed	O
mechanism	O
for	O
the	O
role	O
of	O
IL	B-GP
-	I-GP
17	I-GP
-	O
positive	O
cells	O
in	O
the	O
efficacy	O
of	O
BCG	B-OG
immunotherapy	O
.	O

Recently	O
,	O
a	O
urinary	O
cytokine	B-GP
panel	O
(	O
CyPRIT	O
),	O
based	O
on	O
changes	O
in	O
levels	O
of	O
nine	O
cytokines	B-GP
,	O
correctly	O
identified	O
85	O
.	O
5	O
%	O
of	O
BCG	B-OG
responders	O
in	O
initial	O
tests	O
in	O
130	O
high	O
-	O
risk	O
BCG	B-OG
-	O
treated	O
patients	O
,	O
of	O
whom	O
almost	O
half	O
had	O
concomitant	O
CIS	B-DS
[	O
57	O
].	O

Importantly	O
,	O
of	O
the	O
predictive	O
cytokines	B-GP
,	O
two	O
are	O
induced	O
by	O
IL	B-GP
-	I-GP
17	I-GP
(	O
IL	B-GP
-	I-GP
6	I-GP
and	O
IL	B-GP
-	I-GP
8	I-GP
),	O
and	O
another	O
(	O
TRAIL	O
)	O
is	O
associated	O
with	O
neutrophils	O
recruited	O
by	O
the	O
IL	B-GP
-	I-GP
17	I-GP
/	O
IL	B-GP
-	I-GP
8	I-GP
axis	O
,	O
further	O
supporting	O
IL	B-GP
-	I-GP
17	I-GP
as	O
an	O
important	O
factor	O
in	O
the	O
response	O
to	O
intravesical	O
BCG	B-OG
.	O

Our	O
observations	O
are	O
important	O
for	O
two	O
reasons	O
.	O

Firstly	O
,	O
these	O
data	O
are	O
indicative	O
of	O
a	O
novel	O
mechanism	O
of	O
action	O
of	O
BCG	B-OG
immunotherapy	O
,	O
which	O
could	O
be	O
therapeutically	O
targeted	O
or	O
manipulated	O
,	O
namely	O
mimicking	O
or	O
enhancing	O
the	O
beneficial	O
effects	O
of	O
increased	O
IL	B-GP
-	I-GP
17	I-GP
+	O
MCs	O
.	O

This	O
is	O
a	O
long	O
-	O
term	O
aim	O
that	O
will	O
require	O
a	O
more	O
detailed	O
understanding	O
of	O
whether	O
IL	B-GP
-	I-GP
17	I-GP
+	O
MCs	O
act	O
as	O
effectors	O
or	O
as	O
surrogates	O
of	O
other	O
factors	O
,	O
and	O
confirmation	O
of	O
an	O
event	O
-	O
free	O
survival	O
benefit	O
in	O
a	O
larger	O
study	O
.	O

This	O
work	O
is	O
in	O
progress	O
.	O

Secondly	O
,	O
if	O
confirmed	O
,	O
our	O
results	O
have	O
potential	O
for	O
immediate	O
clinical	O
utility	O
since	O
there	O
are	O
currently	O
no	O
routinely	O
-	O
used	O
biomarkers	O
to	O
predict	O
BCG	B-OG
responses	O
in	O
UBC	B-DS
patients	O
.	O

Incorporating	O
IL	B-GP
-	I-GP
17	I-GP
staining	O
into	O
standard	O
histopathological	O
tumour	B-DS
assessment	O
,	O
or	O
potentially	O
inclusion	O
in	O
CyPRIT	O
,	O
could	O
be	O
a	O
simple	O
way	O
to	O
stratify	O
patients	O
and	O
guide	O
clinical	O
management	O
.	O

Such	O
a	O
stratified	O
approach	O
could	O
reduce	O
the	O
unnecessary	O
toxicity	O
resulting	O
from	O
the	O
futile	O
use	O
of	O
BCG	B-OG
.	O

Supporting	O
information	O

Staining	O
of	O
bladder	B-DS
cancer	I-DS
or	O
control	O
tissue	O
for	O
γδT	O
cells	O
.	O

Tissue	O
sections	O
were	O
stained	O
using	O
a	O
primary	O
antibody	O
specific	O
for	O
the	O
T	O
cell	O
receptor	O
gamma	O
chain	O
,	O
appropriate	O
secondary	O
antibody	O
and	O
DAB	O
.	O

Slides	O
were	O
counterstained	O
with	O
haematoxylin	O
.	O

Shown	O
is	O
a	O
representative	O
result	O
obtained	O
for	O
a	O
bladder	B-DS
cancer	I-DS
biopsy	O
section	O
and	O
a	O
positive	O
control	O
tonsil	O
tissue	O
section	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Control	O
experiment	O
validating	O
the	O
ELANE	B-GP
staining	O
protocol	O
.	O

A	O
positive	O
control	O
tonsillar	O
tissue	O
section	O
was	O
stained	O
for	O
the	O
neutrophil	O
marker	O
ELANE	B-GP
using	O
appropriate	O
antibodies	O
and	O
DAB	O
.	O

The	O
slide	O
was	O
counterstained	O
with	O
haematoxylin	O
.	O

ELANE	B-GP
-	O
positive	O
cells	O
are	O
stained	O
brown	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Table	O
A	O
in	O
S1	O
File	O
:	O
Demographics	O
of	O
bladder	B-DS
cancer	I-DS
patients	O
used	O
to	O
assess	O
IL	B-GP
-	I-GP
17	I-GP
cell	O
infiltration	O
.	O

Table	O
B	O
in	O
S1	O
File	O
:	O
Function	O
of	O
genes	O
changed	O
in	O
5637	O
cells	O
following	O
IL	B-GP
-	I-GP
17	I-GP
treatment	O
.	O

Table	O
C	O
in	O
S1	O
File	O
:	O
Detailed	O
histories	O
of	O
BCG	B-OG
-	O
treated	O
CIS	B-DS
patient	O
outcomes	O
and	O
treatment	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Table	O
A	O
in	O
S2	O
File	O
:	O
Details	O
of	O
antibodies	O
used	O
in	O
immunohistochemistry	O
.	O

Table	O
B	O
in	O
S2	O
File	O
:	O
Details	O
of	O
primers	O
used	O
for	O
quantitative	O
reverse	B-GP
transcriptase	I-GP
PCR	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

